Gain Therapeutics (GANX) Long-Term Debt Issuances (2020)
Gain Therapeutics (GANX) posted Long-Term Debt Issuances of $30396.0 for Q4 2020, down 92.82% on a QoQ basis from $423288.0 in Q3 2020.
Powered by 
Analysis
Gain Therapeutics (GANX) Long-Term Debt Issuances (2020) Analysis & Trends
Gain Therapeutics has reported Long-Term Debt Issuances for 1 years, with the latest figure at $30396.0 in Q4 2020.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $30396.0 in Q4 2020; TTM through Dec 2020 was $738282.0, a N/A change from a year earlier, with the FY2020 full-year figure at $738282.0, changed N/A from the prior year.
- Long-Term Debt Issuances was $30396.0 for Q4 2020 at Gain Therapeutics, down from $423288.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $423288.0 in Q3 2020, with the low at $30396.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Gain Therapeutics | 73.54 Mn | 73.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 30,396.00 |
| Sep 30, 2020 | 423,288.00 |
| Mar 31, 2020 | 284,598.00 |